Histological features | Grade/stage | n | Per cent | CAP (dB/m) | LSM (kPa)* |
---|---|---|---|---|---|
Steatosis | 0 | 7 | 7 | 238 (234–263) | 17.3 (14.5–28.8) |
1 | 38 | 40 | 310 (284–349) | 14.4 (11.6–26.7) | |
2 | 38 | 40 | 324 (303–348) | 13.8 (11.8–17.1) | |
3 | 11 | 12 | 351 (310–393) | 12.8 (7.3–15.3) | |
Lobular inflammation | 0 | 5 | 5 | 263 (249–306) | 14.9 (14.2–20.1) |
1 | 57 | 61 | 318 (283–351) | 14.2 (11.8–22.2) | |
2 | 32 | 34 | 326 (295–351) | 13.7 (9.0–17.1) | |
3 | 0 | 0 | – | – | |
Ballooning | 0 | 40 | 43 | 324 (274–358) | 13.1 (9.3–16.8) |
1 | 47 | 50 | 317 (279–347) | 14.3 (11.9–21.3) | |
2 | 7 | 7 | 310 (299–364) | 26.6 (15.3–36.8) | |
Fibrosis | 0 | 5 | 5 | 235 (204–263) | 8.8 (14.9–18.4) |
1 | 29 | 31 | 341 (310–359) | 11.8 (7.8–12.9) | |
2 | 13 | 14 | 306 (272–341) | 12.6 (7.7–14.4) | |
3 | 20 | 21 | 321 (296–350) | 14.0 (12.7–16.3) | |
4 | 27 | 29 | 323 (292–338) | 23.8 (14.8–35.3) | |
NAFLD activity score | 0–2 | 16 | 17 | 269 (238–331) | 14.5 (13.1–21.3) |
3–4 | 62 | 66 | 319 (288–349) | 14.0 (11.7–21.8) | |
≥5 | 16 | 17 | 333 (321–356) | 14.1 (8.8–16.8) | |
Non-NASH | 41 | 44 | 322 (270–357) | 13.2 (9.9–17.0) | |
NASH | 53 | 56 | 317 (288–347) | 14.5 (11.9–23.8) |
CAP and LSM were expressed in median (IQR).
*The LSM based on M probe examination is shown because only seven patients in this cohort required XL probe measurements.
CAP, controlled attenuation parameter; LSM, liver stiffness measurement; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.